Ísrael - enska - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 6000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).

Ísrael - enska - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 8000 iu / 0.8 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).

Ísrael - enska - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 40000 iu/ml - erythropoietin - erythropoietin - - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.- to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. - treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either:a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males)orb: when the period necessary to obtain the required volume of autologous blood is too short. - perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).

Ísrael - enska - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).

Ísrael - enska - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) orb: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).

Ísrael - enska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: stabilanol is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. stabilanol can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Ísrael - enska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Ísrael - enska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Ísrael - enska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Ísrael - enska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - naproxen sodium - tablets - naproxen sodium 275 mg - naproxen - naproxen - mild and moderate analgesic such as relief of toothache, backache and menstrual pain (primary dysmenorrhea).fever reduction.non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and musculoskeletal inflammations.